Details for Patent: 10,342,791
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 10,342,791 protect, and when does it expire?
Patent 10,342,791 protects ARAKODA and is included in one NDA.
This patent has eight patent family members in seven countries.
Summary for Patent: 10,342,791
| Title: | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects |
| Abstract: | Methods of prevention of symptomatic malaria in a malaria-naive, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I). A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium, during potential exposure of a species of Plasmodium, and after potential exposure of a species of Plasmodium. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naive subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic malaria in malaria-naive, G6PD-normal subjects. ##STR00001## |
| Inventor(s): | Smith; Bryan L (Chevy Chase, MD), Jones; John P (Richmond, VA), Shmuklarsky; Moshe (Bethesda, MD), Balasubrahmanyam; Budda (Richmond, VA) |
| Assignee: | 60 Degrees Pharmaceuticals LLC (Washington, DC) The United States Of America As Represented By The Secretary Of The Army (Washington, DC) |
| Application Number: | 15/532,280 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,342,791
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 Degrees Pharms | ARAKODA | tafenoquine succinate | TABLET;ORAL | 210607-001 | Aug 8, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,342,791
| PCT Information | |||
| PCT Filed | December 02, 2015 | PCT Application Number: | PCT/US2015/063425 |
| PCT Publication Date: | June 09, 2016 | PCT Publication Number: | WO2016/089995 |
International Family Members for US Patent 10,342,791
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015358566 | ⤷ Try a Trial | |||
| Australia | 2020270452 | ⤷ Try a Trial | |||
| Canada | 2968694 | ⤷ Try a Trial | |||
| China | 107683278 | ⤷ Try a Trial | |||
| European Patent Office | 3212621 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
